Download original image
Fig. 2.
PFS following KRd between bortezomib-responsive patients versus bortezomib-refractory patients.
Abbreviations: KRd, carfilzomib, lenalidomide, dexamethasone; PFS, progression-free survival.
Blood Res 2019;54:159~161 https://doi.org/10.5045/br.2019.54.3.159
© Blood Research
© 2024. BLOOD RESEARCH All rights reserved. Powered by INFOrang Co., Ltd